BRISTOL MYERS SQUIBB

🇫🇷France
Ownership
-
Established
1989-01-01
Employees
30K
Market Cap
$97.5B
Website
https://www.bms.com/

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

First Posted Date
2004-06-11
Last Posted Date
2022-04-14
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
77
Registration Number
NCT00084656
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States

Study of MDX-010 in Stage IV Breast Cancer

Phase 2
Completed
Conditions
First Posted Date
2004-05-20
Last Posted Date
2012-04-27
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
33
Registration Number
NCT00083278
Locations
🇺🇸

LaGrange, LaGrange, Kentucky, United States

🇺🇸

Sharp Clinical Oncology Research, San Diego, California, United States

🇺🇸

Medical Arts Building, Jeffersonville, Indiana, United States

and more 8 locations

Effectiveness of KOS-862 in the Treatment of Lung Cancer

Phase 2
Terminated
Conditions
First Posted Date
2004-04-07
Last Posted Date
2010-02-03
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
85
Registration Number
NCT00080509

BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy

Phase 2
Completed
Conditions
First Posted Date
2003-09-09
Last Posted Date
2013-04-05
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT00017043
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy

First Posted Date
2003-08-28
Last Posted Date
2011-04-14
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT00067782
Locations
🇺🇸

Local Institution, Houston, Texas, United States

Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation

Phase 3
Completed
Conditions
Interventions
First Posted Date
2003-07-29
Last Posted Date
2013-06-24
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
195
Registration Number
NCT00065507
Locations
🇺🇸

California Pacific Medical Center, San Francisco, California, United States

🇬🇷

Local institution, Athens, Greece

🇺🇸

Mount Sinai Medical Center, New York, New York, United States

and more 16 locations

A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors

Phase 2
Completed
Conditions
Interventions
First Posted Date
2003-04-03
Last Posted Date
2011-04-14
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT00057473
Locations
🇺🇸

Local Institution, Houston, Texas, United States

Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors

First Posted Date
2003-01-27
Last Posted Date
2013-04-05
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT00024284
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

🇺🇸

Arizona Cancer Center, Tucson, Arizona, United States

🇺🇸

Children's National Medical Center, Washington, District of Columbia, United States

and more 4 locations

Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients

Phase 2
Completed
Conditions
First Posted Date
2003-01-03
Last Posted Date
2011-04-14
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT00051038
Locations
🇺🇸

Local Institution, Pittsburgh, Pennsylvania, United States

Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer

Phase 2
Completed
Conditions
First Posted Date
2002-12-17
Last Posted Date
2011-06-27
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT00050596
Locations
🇺🇸

University Urological Research Institute, Providence, Rhode Island, United States

🇺🇸

Pacific Shores Medical Group, Long Beach, California, United States

🇺🇸

San Diego Uro-Research, San Diego, California, United States

and more 8 locations
© Copyright 2024. All Rights Reserved by MedPath